ALLO · Company research
Allogene Therapeutics, Inc. Common Stock (ALLO): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 1.46 | $396,479,790.3 | 366170790.30 | — | — | — | — | 1.4217114847153743 | — |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.